Background::Hepatitis B is a viral infection that attacks the liver and can cause both potentially life-threatening acute and chronic liver disease.China has the world’s largest burden of hepatitis B and is considere...Background::Hepatitis B is a viral infection that attacks the liver and can cause both potentially life-threatening acute and chronic liver disease.China has the world’s largest burden of hepatitis B and is considered to be a major contributor toward the goal of World Health Organization(WHO)of eliminating hepatitis B virus(HBV)as a global health threat by 2030.This study aimed to analyze data from the Global Burden of Diseases,Injuries,and Risk Factors Study(GBD)to determine the trends in mortality of liver disease due to hepatitis B in China between 1990 and 2019 and the gap with the WHO’s goal.Methods::Annual deaths and age-standardized mortality rates(ASMRs)of liver disease due to hepatitis B in China between 1990 and 2019 were collected from GBD 2019.We calculated the percentage changes in deaths and estimated annual percentage changes(EAPCs)of ASMRs of liver disease due to hepatitis B.Results::In China,deaths of total liver disease due to hepatitis B decreased by 29.13%from 229 thousand in 2016 to 162 thousand in 2019,and ASMR decreased by an average of 4.92%(95%confidence interval[CI]:4.45–5.39%)per year in this period.For the spectrum of liver disease due to hepatitis B,deaths decreased by 74.83%,34.71%,and 23.34%for acute hepatitis,cirrhosis and other chronic liver diseases,and liver cancer from 1990 to 2019,respectively,and ASMRs of acute hepatitis(EAPC=–7.63;95%CI:–8.25,–7.00),cirrhosis and other chronic liver diseases(EAPC=–4.15;95%CI:–4.66,–3.65),and liver cancer(EAPC=–5.17;95%CI:–6.00,–4.33)decreased between 1990 and 2019.The proportions of older adults aged≥70 years among all deaths of the spectrum of liver disease due to hepatitis B increased from 1990 to 2019.Deaths of liver cancer due to hepatitis B increased by 7.05%from 2015 to 2019.Conclusions::Although a favorable trend in the mortality of liver disease due to hepatitis B was observed between 1990 and 2019,China still faces challenges in achieving the WHO’s goal of eliminating HBV as a public threat by 2030.Therefore,efforts to increase the coverage of diagnosis and treatment of liver disease due to hepatitis B,especially of liver cancer due to hepatitis B,are warranted in China.展开更多
With the increasing incidence of obesity and metabolic syndrome worldwide,concomitant nonalcoholic fatty liver disease(NAFLD)in patients with chronic hepatitis B(CHB)has become highly prevalent.The risk of dual etiolo...With the increasing incidence of obesity and metabolic syndrome worldwide,concomitant nonalcoholic fatty liver disease(NAFLD)in patients with chronic hepatitis B(CHB)has become highly prevalent.The risk of dual etiologies,outcome,and mechanism of CHB with concomitant NAFLD have not been fully characterized.In this review,we assessed the overlapping prevalence of metabolic disorders and CHB,assessed the risk of advanced fibrosis/hepatocellular carcinoma in CHB patients concomitant with NAFLD,and discussed the remaining clinical issues to be addressed in the outcome of such patients.We also explored the possible roles of hepatitis B virus in the development of steatosis and discussed difficultiesof histological evaluation.For CHB patients,it is important to address concomitant NAFLD through lifestyle management and disease screening to achieve better prognoses.The assessment of progressive changes and novel therapies for CHB patients concomitant with NAFLD deserve further research.展开更多
Objective:The purpose of this study was to analyze the economic burden of inpatients with hepatitis B virus(HBV)-related diseases and the influencing factors so as to provide an effective basis for the development of ...Objective:The purpose of this study was to analyze the economic burden of inpatients with hepatitis B virus(HBV)-related diseases and the influencing factors so as to provide an effective basis for the development of health prevention and control strategies.Methods:The patients were selected by means of successive sampling in the period between August and December 2012 from those who were diagnosed with HBV-related diseases and hospitalized in countylevel medical institutions of Jiangsu Province.One hundred ninety-six patients were studied,including 3 patients with acute HBV,141 with chronic HBV,18 with compensatory cirrhosis,22 with decompensated cirrhosis,and 12 with liver cancer.This study adopted a questionnaire method to investigate and calculate the direct and indirect economic burden of the subjects according to disease economic burden theories and methods.Multiple linear stepwise regression was used for analysis of the influencing factors for economic burden of inpatients with HBV-related diseases.Results:The average economic burden for the 196 inpatients investigated was RMB 28,971.The direct economic burden was RMB 19,916(68.7%),including direct medical costs(RMB 19,087;95.8%)and direct non-medical costs(RMB 829;4.2%).The indirect economic burden was RMB 9055(31.3%),including patient-related expenses(RMB 6348;70.1%)and nursing expenses(RMB 2707;29.9%).According to the multiple linear stepwise regression analysis results,the hospital stay,proportion of medicine,age,and disease type affected the economic burden of the patients(P<0.05).Conclusion:Patients with HBV-related diseases undertake a heavy economic burden for hospitalization,especially the direct economic burden.Therefore,the inpatients’economic burden can be reduced by shortening the hospital stay,reducing the medical expenses reasonably,and delaying the progression of disease as far as possible according to medical standards.展开更多
Background::China and the United States(US)ranked first and third in terms of new liver cancer cases and deaths globally in 2020.Therefore,a comprehensive assessment of trends in the incidence of primary liver cancer ...Background::China and the United States(US)ranked first and third in terms of new liver cancer cases and deaths globally in 2020.Therefore,a comprehensive assessment of trends in the incidence of primary liver cancer with four major etiological factors between China and the US during the past 30 years with age-period-cohort(APC)analyses is warranted.Methods::Data were obtained from the Global Burden of Disease 2019,and period/cohort relative risks were estimated by APC modeling from 1990 to 2019.Results::In 2019,there were 211,000 new liver cancer cases in China and 28,000 in the US,accounting for 39.4%and 5.2%of global liver cancer cases,respectively.For China,the age-standardized incidence rate(ASIR)consecutively decreased before 2005 but increased slightly since then,whereas the ASIR continuously increased in the US.Among the four etiological factors of liver cancer,the fastest reduction in incidence was observed in hepatitis B virus-related liver cancer among Chinese women,and the fastest increase was in nonalcoholic steatosis hepatitis(NASH)-related liver cancer among American men.The greatest reduction in the incidence of liver cancer was observed at the age of 53 years in Chinese men(-5.2%/year)and 33 years in Chinese women(-6.6%/year),while it peaked at 58 years old in both American men and women(4.5%/year vs.2.8%/year).Furthermore,the period risks of alcohol-and NASH-related liver cancer among Chinese men have been elevated since 2013.Simultaneously,leveled-off period risks were observed in hepatitis C viral-related liver cancer in both American men and women.Conclusions::Currently,both viral and lifestyle factors have been and will continue to play an important role in the time trends of liver cancer in both countries.More tailored and efficient preventive strategies should be designed to target both viral and lifestyle factors to prevent and control liver cancer.展开更多
目的了解2019年中国乙型肝炎的疾病负担情况并对2020—2030年乙型肝炎的疾病负担发展趋势进行预测。方法在2019全球疾病负担研究数据库(Global Burden of Disease 2019,GBD 2019)中下载中国乙型肝炎数据。利用患病率、发病率、死亡率、...目的了解2019年中国乙型肝炎的疾病负担情况并对2020—2030年乙型肝炎的疾病负担发展趋势进行预测。方法在2019全球疾病负担研究数据库(Global Burden of Disease 2019,GBD 2019)中下载中国乙型肝炎数据。利用患病率、发病率、死亡率、伤残调整寿命年(disability-adjusted life year,DALY)、早死损失寿命年(years of life lost,YLL)、伤残损失寿命年(years lived with disability,YLD)及年龄标化率等指标描述2019年中国乙型肝炎的疾病负担情况,利用估计年百分比变化(estimated annual percentage change,EAPC)描述中国乙型肝炎疾病负担1990—2019年的变化趋势。采用R4.2.1构建贝叶斯年龄-时期-队列模型对2020—2030年中国乙型肝炎总体发病、死亡、DALY和YLD情况进行预测。结果1990—2019年中国乙型肝炎的总体疾病负担呈下降趋势,中国乙型肝炎的总体标化患病率为6566.1/10万、标化发病率为1397.3/10万、标化死亡率为8.1/10万、标化DALY率为247.7/10万、标化YLL率为241.5/10万、标化YLD率为6.2/10万,与1990年相比分别下降2.34%、2.35%、4.92%、5.15%、5.20%、2.71%。女性居民的疾病负担指标均低于同时期的男性居民。乙型肝炎的患病率在20~24岁最高,发病率在25~29岁最高,死亡率随着年龄增长而升高。根据贝叶斯模型预测,2020—2030年中国乙型肝炎发病人数约为1486.56万人,死亡人数约为11.18万人,DALY约为634.9万人年,YLD约为12.1万人年。结论尽管在1990—2019年之间中国乙型肝炎疾病负担呈下降趋势,但在2030年消除乙型肝炎病毒这一公共威胁的目标仍然面临挑战。因此,有必要扩大诊断覆盖范围、减轻患者经济负担,进一步推进健康中国建设。展开更多
基金This work was supported by grants from the National Key Research and Development Program of China(Nos.2021ZD0114104,2021ZD0114105,and 2021ZD0114101).
文摘Background::Hepatitis B is a viral infection that attacks the liver and can cause both potentially life-threatening acute and chronic liver disease.China has the world’s largest burden of hepatitis B and is considered to be a major contributor toward the goal of World Health Organization(WHO)of eliminating hepatitis B virus(HBV)as a global health threat by 2030.This study aimed to analyze data from the Global Burden of Diseases,Injuries,and Risk Factors Study(GBD)to determine the trends in mortality of liver disease due to hepatitis B in China between 1990 and 2019 and the gap with the WHO’s goal.Methods::Annual deaths and age-standardized mortality rates(ASMRs)of liver disease due to hepatitis B in China between 1990 and 2019 were collected from GBD 2019.We calculated the percentage changes in deaths and estimated annual percentage changes(EAPCs)of ASMRs of liver disease due to hepatitis B.Results::In China,deaths of total liver disease due to hepatitis B decreased by 29.13%from 229 thousand in 2016 to 162 thousand in 2019,and ASMR decreased by an average of 4.92%(95%confidence interval[CI]:4.45–5.39%)per year in this period.For the spectrum of liver disease due to hepatitis B,deaths decreased by 74.83%,34.71%,and 23.34%for acute hepatitis,cirrhosis and other chronic liver diseases,and liver cancer from 1990 to 2019,respectively,and ASMRs of acute hepatitis(EAPC=–7.63;95%CI:–8.25,–7.00),cirrhosis and other chronic liver diseases(EAPC=–4.15;95%CI:–4.66,–3.65),and liver cancer(EAPC=–5.17;95%CI:–6.00,–4.33)decreased between 1990 and 2019.The proportions of older adults aged≥70 years among all deaths of the spectrum of liver disease due to hepatitis B increased from 1990 to 2019.Deaths of liver cancer due to hepatitis B increased by 7.05%from 2015 to 2019.Conclusions::Although a favorable trend in the mortality of liver disease due to hepatitis B was observed between 1990 and 2019,China still faces challenges in achieving the WHO’s goal of eliminating HBV as a public threat by 2030.Therefore,efforts to increase the coverage of diagnosis and treatment of liver disease due to hepatitis B,especially of liver cancer due to hepatitis B,are warranted in China.
基金Supported by National Key Research and Development Program of China,No.2017YFC0908903National Natural Science Foundation of China,No.81873565 and No.81900507.
文摘With the increasing incidence of obesity and metabolic syndrome worldwide,concomitant nonalcoholic fatty liver disease(NAFLD)in patients with chronic hepatitis B(CHB)has become highly prevalent.The risk of dual etiologies,outcome,and mechanism of CHB with concomitant NAFLD have not been fully characterized.In this review,we assessed the overlapping prevalence of metabolic disorders and CHB,assessed the risk of advanced fibrosis/hepatocellular carcinoma in CHB patients concomitant with NAFLD,and discussed the remaining clinical issues to be addressed in the outcome of such patients.We also explored the possible roles of hepatitis B virus in the development of steatosis and discussed difficultiesof histological evaluation.For CHB patients,it is important to address concomitant NAFLD through lifestyle management and disease screening to achieve better prognoses.The assessment of progressive changes and novel therapies for CHB patients concomitant with NAFLD deserve further research.
基金National Science and Technology Major Project-Study on Large-scale Field epidemiology and Interventions for AIDS Prevention,Virus Hepatitis,Tuberculosis and other Major Infectious Diseases[2011ZX10004902]。
文摘Objective:The purpose of this study was to analyze the economic burden of inpatients with hepatitis B virus(HBV)-related diseases and the influencing factors so as to provide an effective basis for the development of health prevention and control strategies.Methods:The patients were selected by means of successive sampling in the period between August and December 2012 from those who were diagnosed with HBV-related diseases and hospitalized in countylevel medical institutions of Jiangsu Province.One hundred ninety-six patients were studied,including 3 patients with acute HBV,141 with chronic HBV,18 with compensatory cirrhosis,22 with decompensated cirrhosis,and 12 with liver cancer.This study adopted a questionnaire method to investigate and calculate the direct and indirect economic burden of the subjects according to disease economic burden theories and methods.Multiple linear stepwise regression was used for analysis of the influencing factors for economic burden of inpatients with HBV-related diseases.Results:The average economic burden for the 196 inpatients investigated was RMB 28,971.The direct economic burden was RMB 19,916(68.7%),including direct medical costs(RMB 19,087;95.8%)and direct non-medical costs(RMB 829;4.2%).The indirect economic burden was RMB 9055(31.3%),including patient-related expenses(RMB 6348;70.1%)and nursing expenses(RMB 2707;29.9%).According to the multiple linear stepwise regression analysis results,the hospital stay,proportion of medicine,age,and disease type affected the economic burden of the patients(P<0.05).Conclusion:Patients with HBV-related diseases undertake a heavy economic burden for hospitalization,especially the direct economic burden.Therefore,the inpatients’economic burden can be reduced by shortening the hospital stay,reducing the medical expenses reasonably,and delaying the progression of disease as far as possible according to medical standards.
基金The study was sponsored by research grants from the National Natural Science Foundation of China(Nos.81773454 and 82073573)Discipline Construction Funding of Public Health and Preventive Medicine from PekingUniversity Health Science Center(No.BMU2020XY010).
文摘Background::China and the United States(US)ranked first and third in terms of new liver cancer cases and deaths globally in 2020.Therefore,a comprehensive assessment of trends in the incidence of primary liver cancer with four major etiological factors between China and the US during the past 30 years with age-period-cohort(APC)analyses is warranted.Methods::Data were obtained from the Global Burden of Disease 2019,and period/cohort relative risks were estimated by APC modeling from 1990 to 2019.Results::In 2019,there were 211,000 new liver cancer cases in China and 28,000 in the US,accounting for 39.4%and 5.2%of global liver cancer cases,respectively.For China,the age-standardized incidence rate(ASIR)consecutively decreased before 2005 but increased slightly since then,whereas the ASIR continuously increased in the US.Among the four etiological factors of liver cancer,the fastest reduction in incidence was observed in hepatitis B virus-related liver cancer among Chinese women,and the fastest increase was in nonalcoholic steatosis hepatitis(NASH)-related liver cancer among American men.The greatest reduction in the incidence of liver cancer was observed at the age of 53 years in Chinese men(-5.2%/year)and 33 years in Chinese women(-6.6%/year),while it peaked at 58 years old in both American men and women(4.5%/year vs.2.8%/year).Furthermore,the period risks of alcohol-and NASH-related liver cancer among Chinese men have been elevated since 2013.Simultaneously,leveled-off period risks were observed in hepatitis C viral-related liver cancer in both American men and women.Conclusions::Currently,both viral and lifestyle factors have been and will continue to play an important role in the time trends of liver cancer in both countries.More tailored and efficient preventive strategies should be designed to target both viral and lifestyle factors to prevent and control liver cancer.
文摘目的了解2019年中国乙型肝炎的疾病负担情况并对2020—2030年乙型肝炎的疾病负担发展趋势进行预测。方法在2019全球疾病负担研究数据库(Global Burden of Disease 2019,GBD 2019)中下载中国乙型肝炎数据。利用患病率、发病率、死亡率、伤残调整寿命年(disability-adjusted life year,DALY)、早死损失寿命年(years of life lost,YLL)、伤残损失寿命年(years lived with disability,YLD)及年龄标化率等指标描述2019年中国乙型肝炎的疾病负担情况,利用估计年百分比变化(estimated annual percentage change,EAPC)描述中国乙型肝炎疾病负担1990—2019年的变化趋势。采用R4.2.1构建贝叶斯年龄-时期-队列模型对2020—2030年中国乙型肝炎总体发病、死亡、DALY和YLD情况进行预测。结果1990—2019年中国乙型肝炎的总体疾病负担呈下降趋势,中国乙型肝炎的总体标化患病率为6566.1/10万、标化发病率为1397.3/10万、标化死亡率为8.1/10万、标化DALY率为247.7/10万、标化YLL率为241.5/10万、标化YLD率为6.2/10万,与1990年相比分别下降2.34%、2.35%、4.92%、5.15%、5.20%、2.71%。女性居民的疾病负担指标均低于同时期的男性居民。乙型肝炎的患病率在20~24岁最高,发病率在25~29岁最高,死亡率随着年龄增长而升高。根据贝叶斯模型预测,2020—2030年中国乙型肝炎发病人数约为1486.56万人,死亡人数约为11.18万人,DALY约为634.9万人年,YLD约为12.1万人年。结论尽管在1990—2019年之间中国乙型肝炎疾病负担呈下降趋势,但在2030年消除乙型肝炎病毒这一公共威胁的目标仍然面临挑战。因此,有必要扩大诊断覆盖范围、减轻患者经济负担,进一步推进健康中国建设。
